Cyclosporine A Drug-Delivery System for High-risk Keratoplasty
We read the article by Shi et al reporting the efficacy of a novel cyclosporine (CsA) drug delivery system (DDS) for suppressing the occurrence of rejection and improving the survival of corneal allografts after high-risk keratoplasty with great interest. In this noncomparative case series consisting of 92 patients (92 eyes), the researchers demonstrated that the CsA DDS implanted in the anterior chamber was effective for the prophylaxis of immune rejection after high-risk keratoplasty. Furthermore, this DDS functioned without toxicity to the cornea and the iris of the patients. It can also (Read more...)